## **Supplementary Figures**



**Fig. S1** Schematic descriptions of glucose metabolism (**a**) and GOx for tumor starvation by glucose consumption (**b**). Schematic descriptions of mannose for metabolic disturbance (**c**) and synergistic glycolysis inhibition through mannose plus GOx (**d**)



Fig. S2 Zeta potential of ZIF-8 (a), ZIF-8/M (b), ZIF-8/G (c), and ZIF-8/M&G (d) nanoparticles



**Fig. S3** (a) Hydrodynamic size of ZIF-8 and ZIF-8/M&G. (b) PDI of ZIF-8 and ZIF-8/M&G



Fig. S4 (a) Fluorescent images of A549 cells incubated with ZIF-8/Ce6 for different time points. (b) Fluorescent intensity of A549 cells incubated with ZIF-8/Ce6 for different time points. N = 20, \*P < 0.05, \*\*P < 0.01, \*\*\*\*P < 0.0001 and ns: not significant (P > 0.05). Data represent mean  $\pm$  SD. (c) Fluorescent images of A549 and HUVEC cells incubated with ZIF-8/Dil for 2 h



**Fig. S5** Comparison of hematology data of healthy Balb/c mice at two months after intravenous injection of ZIF-8/M&G nanoparticles at a dosage of 16 mg/kg. An equal volume of PBS was used as a control. WBCs: white blood cells; RBCs: red blood cells; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red blood cell distribution width coefficient of variation; PLT: platelet; MPV: mean platelet volume; PDW: platelet distribution width; and PCT: procalcitonin. N = 5, \*P < 0.05, \*\*P < 0.01, \*\*\*\*P < 0.0001 and ns: not significant (P > 0.05). Data represent mean  $\pm$  SD